Business
MedMira Invites Investment Analysts to Conference Call
HALIFAX, July 18 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) a developer ...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n\nHALIFAX, July 18 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF) a developer and marketer of rapid diagnostics, announced today\nthat its president and CEO, Hermes Chan, will host a conference call with\nanalysts to discuss the company's recent patent announcement and new growth\nopportunities for MedMira's rapid flow-through technology platform, beginning\nat 1:00 pm EST (2:00 pm AST) on Monday, July 21, 2008.\n\n\nIn order to listen to the conference call, please dial 1-800-732-9307\ntoll-free anywhere in Canada or the USA, or 1-416-644-3418 in the Toronto\narea.\n\n\nA replay of the call will be available until 23:59 pm EST, Monday,\nJuly 28, 2008 and may be accessed by dialing 1-877-289-8525 toll-free anywhere\nin Canada or the USA, or 1-416-640-1917 in the Toronto area, and entering the\npass code 21278759(number sign) anytime after the call has ended.\n\n\nAbout MedMira\n\n\nMedMira is a leading developer, manufacturer, and marketer of advanced\nrapid diagnostics. Built on the Company's patented rapid flow-through\ntechnology platform, MedMira's single and multiple rapid tests provide\nhospitals, labs, clinics and individuals around the world with reliable,\ndiagnosis for diseases such as HIV and hepatitis C in just three minutes. The\ncompany's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM)\nand Multiplo(TM) brands in global markets, have achieved regulatory approvals\nin Canada, the United States, China, Russia, India, and the European Union.\nMedMira is an approved supplier to US Agency for International Development\n(USAID) and the Pan American Health Organization (PAHO).\n\n\nIn 2006, MedMira launched the Maple Biosciences division to develop and\ncommercialize diagnostic instruments based on biosensor technology platforms.\nThe new diagnostic solutions will enable routine laboratory tests to be\nperformed in a matter of minutes, increasing automation, and streamlining the\ndiagnosis of multiple conditions and diseases. Together MedMira and Maple\nBiosciences will be leading participants in the emerging fields of\npersonalized medicine and molecular diagnostics. For more information visit\nwww.maplebio.com.\n\n\nMedMira's corporate offices, R&D, and manufacturing facilities are\nlocated in Halifax, Nova Scotia, Canada. For more information visit MedMira'...